Endogenous ocular candidiasis: changes in epidemiology and factors associated with poor functional outcome.
The evolution of the incidence and the epidemiology of ocular candidiasis in our hospital during the past 12 y, as well as the factors associated with poor functional outcome were analysed. A retrospective study of all cases of ocular candidiasis admitted to a university hospital between 1993 and 2004 was performed. Epidemiological, clinical and final outcome data were recorded. 37 episodes of ocular candidiasis in 36 patients were studied. 28 (75%) episodes occurred between 1993 and 1998 (13.09 episodes/100,000 admissions/y), and all of these patients were intravenous drug users. In contrast, only 9 episodes of ocular candidiasis were recorded between 1999 and 2004 (4.42 episodes/100,000 admissions/y; p<.0001) and 3 (33%) patients were not drug users (p<0.01). 19 (57%) cases had final visual acuity <0.1. Treatment with conventional amphotericin B instead of other newer antifungal drugs was associated with poor visual prognosis in the univariate (p = 0.03) and multivariate (p = 0.03) analysis. In conclusion, the incidence of ocular candidiasis has decreased significantly in recent y and the epidemiology has changed. Currently, one-third of patients are immunocompromised non-drug users. Therapy with conventional amphotericin B instead of newer antifungal drugs appears to be associated with a poorer functional outcome.
Horcajada
Juan P
JP
Infectious Diseases Unit, Hospital Universitario Marqués de Valdecilla, University of Cantabria, School of Medicine, Santander (Cantabria), Spain.
Fernández-Sampedro
Marta
M
García-Palomo
Daniel
D
Cañal
Joaquín
J
Salesa
Ricardo
R
Farinas
María C
MC
D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D002177:Candidiasis / Q000188:drug therapy / Q000453:epidemiology* / Q000503:physiopathology; D015821:Eye Infections, Fungal / Q000188:drug therapy / Q000453:epidemiology* / Q000503:physiopathology; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D008297:Male; D011379:Prognosis; D012189:Retrospective Studies; D013030:Spain / Q000453:epidemiology; D015819:Substance Abuse, Intravenous / Q000453:epidemiology / Q000382:microbiology; D016896:Treatment Outcome; D014792:Visual Acuity
D000935:Antifungal Agents; D000666:Amphotericin B; D015725:Fluconazole